Novartis’ experimental cardiovascular drug fails a pivotal study
Other pharmaceutical companies, including Amgen and Eli Lilly, are also developing therapies to lower levels of Lp(a).
News Search
Search results for Novartis’ experimental cardiovascular drug fails a pivotal study
Search Results
1 results found